
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a financially sound company with a solid product portfolio and a strong presence in the global market. With a focus on innovation and plans for future product releases, the company is well-equipped to capitalize on the significant market size for their products. Their vertically integrated approach and strong partnerships give them a competitive advantage and position them for revenue growth. Additionally, improved operations are expected to result in cost savings for the company.
Bears say
Minimed Group is a leader in algorithm development for diabetes management and has seen positive clinical outcomes with its AID systems and smart multiple daily injection (MDI) systems. However, with a projected turnaround to positive cash flow not expected until FY2027 and potential pricing pressure and penetration concerns, the company's profitability and growth potential may be limited. Additionally, regulatory and reimbursement risks, intense competition, and the influence of Medtronic, its parent company, are all potential obstacles to its success.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares